Bristol Readies For Prasugrel’s Impact On Plavix, Files DPP-4 Inhibitor

Despite downplaying any concern, Bristol-Myers Squibb is preparing for a potential challenge to its blockbuster anti-clotting drug Plavix from Lilly/Daiichi Sankyo's Effient (prasugrel)